Number of eligible clients: CDEC talked over the uncertainty in the volume of people with reasonably intense to intense hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some people who will be categorised as obtaining modera